MenACWY booster and 5-year antibody persistence study in previously vaccinated adolescents

Phase 2, open-label trial of Meningococcal ACWY conjugate vaccine in meningococcal disease (2 arms), sponsored by Novartis. Primary endpoint: Percentage of participants with serum bactericidal activity >=1:8 at 5 years after primary vaccination.